and decreasing adverse respiratory symptoms (13 ) . THC is highly lipophilic, rapidly distributing to highly perfused tissues, and later to fat (14 ) . Blood and plasma smoked cannabinoid disposition was recently evaluated in occasional and frequent cannabis smokers (15) (16) , but vaporized cannabis disposition is not yet fully characterized. The few prior clinical studies had short (Յ6 h) time courses and limited metabolite analyses (10 -11 ) . As medical cannabis use increases, data on plasma cannabinoids after vaporized cannabis are needed for therapeutic optimization, and blood cannabinoid data are needed for forensic DUI cannabis cases (17 ) .
In this study, we simultaneously evaluated phase I and II cannabinoid disposition in blood and plasma after controlled vaporized cannabis administration, with and without low-dose oral alcohol administration. We hypothesized that cannabinoid delivery and disposition would be similar to that observed with smoking, and that alcohol would not substantially impact cannabinoid pharmacokinetics.
Methods

PARTICIPANTS
Healthy adults provided written informed consent for this University of Iowa Institutional Review Boardapproved study. Inclusion criteria were ages 21-55 years; self-reported mean cannabis consumption Ն1 time/3 months but Յ3 days/week over the past 3 months (Cannabis Use Disorders Identification Test (18 ) ); selfreported "light" or "moderate" alcohol consumption according to a quantity-frequency-variability scale (19 ) ; or if "heavy," not more than 3-4 servings in a typical drinking occasion. Exclusion criteria included past or current clinically significant medical illness; history of clinically significant adverse event associated with cannabis/alcohol intoxication; Ն450 mL blood donation in the 2 weeks preceding drug administration; pregnant/nursing; interest in drug abuse treatment within the past 60 days; and currently taking drugs contraindicated with cannabis or alcohol (ethanol) or known to affect driving.
STUDY DESIGN
Participants entered the clinical research unit 10 -16 h before drug administration to preclude intoxication at dosing. Over 10 min, participants drank ad libitum placebo (Ϫ) (apple, orange, or cranberry juice, consistent within individuals, with ethanol-swabbed rim and topped with 1 mL ethanol to mimic alcohol taste and odor) or low-dose (ϩ) 90% grain ethanol (to produce approximately 0.065% peak breath alcohol concentration) mixed with juice. After drinking, they orally inhaled 500 mg placebo (P) [ Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/vol61/ issue6). We obtained bulk cannabis through the National Institute on Drug Abuse (NIDA) Chemistry and Physiological Systems Research Branch. In this withinindividual design, participants received all 6 alcohol/cannabis doses, in randomized order, in sessions separated by Ն1 week to prevent cannabinoid carryover from study interventions. Blood was collected via indwelling peripheral venous catheter into gray-top potassium oxalate/sodium fluoride Vacutainer ® tubes (VWR Scientific) at baseline (Ϫ0.8 h) and 0.17, 0.42, 1.4, 2.3, 3.3, 4.8, 6.3, and 8.3 h after start of inhalation, stored on ice Յ2 h, with a second sample centrifuged at 1600g for 10 min. Blood and plasma were transferred into 3.6-mL Nunc ® cryotubes (Thomas Scientific), stored at Ϫ20°C, and analyzed within 3 months, on the basis of our previous stability study (20 ) .
BLOOD AND PLASMA ANALYSIS
We quantified blood and plasma cannabinoids by a previously published LC-MS/MS method (21 ) . Briefly, 0.5 mL blood or plasma was protein-precipitated with icecold acetonitrile, and supernatants were diluted and solid-phase extracted with Bond-Elut Plexa cartridges (Agilent Technologies). Linear ranges were 1-100 g/L for THC, 11-hydroxy-THC (11-OH-THC), 11-nor-9-carboxy-THC (THCCOOH), CBD, and CBN; 5-250 g/L for THCCOOH-glucuronide; and 0.5-50 g/L for THC-glucuronide. Interassay (n ϭ 30) analytical accuracy and imprecision were 93.1%-109.3% and 4.5%-12.8%, respectively.
DATA ANALYSIS
We performed noncompartmental analyses with Phoenix WinNonLin ® 6.3 for Windows (Pharsight). Maximum concentration (C max ), C max accounting for baseline (C max-BL ), time to maximum concentration (t max ), area under the curve (AUC) from 0 to 8.3 h postdose (AUC 0-8.3h ), AUC 0 -8.3h accounting for baseline (AUC ), time of last observed concentration (t last ), and last observed concentration (C last ) were compared with SPSS ® Statistics version 19 for Windows (IBM). For statistical purposes, concentrations less than the limit of quantification (LOQ) were set to 0. We compared overall alcohol and cannabis effects on pharmacokinetic parameters for each analyte with factorial repeated-measures ANOVA (factors: cannabis, alcohol, cannabis * alcohol) with Bonfer-roni correction for individuals who completed all 6 sessions. When the Mauchly sphericity test was violated, the Greenhouse-Geisser correction was used. Friedman's ANOVA with pairwise post hoc comparisons was used to determine within-individual dose differences, overall and by time point. For time point analyses, we used the conservative Bonferroni correction for multiple comparisons (P Ͻ 0.05/9 measurements ϭ P Ͻ 0.006). Blood/plasma or metabolite ratios were calculated when quantifiable (positive) data were available. We assessed THCCOOHglucuronide/THCCOOH ratios with factorial repeatedmeasures ANOVA in SPSS, with factors alcohol and cannabis, and covariate time.
Results
PARTICIPANTS
Thirty-two healthy adults (22 men, ages 21-42 years, 72% white) participated in the study (Table 1) . Most participants consumed cannabis Ն2 times/month and reported intake within a week before admission. Two individuals (participants 17 and 20) self-reported last intake 4 and 6 months ago, respectively, despite reporting overall mean consumption at Ն1 time/3 months. Nineteen participants completed all 6 sessions (PϪ/ϩ, LϪ/ϩ, HϪ/ϩ); there were no significant differences in cannabis history, age, or body mass index between these and the 13 noncompleters [Mann-Whitney U (exact) test]. One participant (24 ) withdrew due to nausea/emesis from cannabis administration; other noncompleters withdrew for personal reasons.
BLOOD AND PLASMA CANNABINOIDS
In total, 1324 blood and 1327 plasma samples were quantified for cannabinoids. Blood and plasma pharmacokinetic parameters for 19 completers are presented in Tables 2-4 and online Supplemental Tables 2-4 . Blood C max , with and without accounting for baseline concentrations for THC, 11-OH-THC, and CBN, were significantly higher when alcohol was coadministered with cannabis; in addition, blood THCCOOH-glucuronide t max was earlier and blood CBN AUC 0 -8.3h was higher with concomitant alcohol (Table 3 and online Supplemental Table 3 ). In plasma, alcohol significantly increased THC, 11-OH-THC, and CBN C max and CBD C max-BL (Table 4 and online Supplemental Table 4 ). Significant additional alcohol-cannabis interactions were observed for 11-OH-THC (C max , C last , t last in blood; C last in plasma) and plasma CBD (C max ). Blood and plasma THC AUC 0 -8.3h L and H doses were significantly higher than placebo (P Ͻ 0.001 and P ϭ 0.036 respectively, in both blood and plasma). Accounting for baseline revealed a significant overall cannabis effect on AUC ϾBL-8.3h and significantly higher AUC ϾBL-8.3h after H vs L cannabis. Significant overall cannabinoid concentration differences (P Ͻ 0.006) were observed in blood through 3.3 h ( Fig. 1 and online Supplemental Fig. 1 ) for THC and 11-OH-THC, throughout the time course for THC-COOH, and beginning at 1.4 h for THCCOOHglucuronide. Only HϪ and Hϩ showed significant THCCOOH-glucuronide differences (post hoc analysis) relative to PϪ and Pϩ. Plasma observations were similar to blood ( Fig. 1 and online Supplemental Fig. 2) . Fig. 1 and online Supplemental Figs. 2 and 3 present post hoc within-individual dose differences at individual collection times. No significant blood or plasma L vs H cannabinoid differences were observed at any discrete time point for any analyte except plasma CBD immediately postinhalation (Fig. 1) . Median THC-glucuronide, CBD, and CBN t last occurred within 0.5 h after inhalation. For all dosing conditions, Ն10.5% completers had blood THC Ն1 g/L at baseline and Ն16.7% throughout 8.3 h postdose, even after placebo cannabis (Fig. 2) . With a 2 g/L blood THC cutoff, 5.3%-10.5% were positive at baseline for all doses, and only 1 participant was positive after 0.42 h for PϪ. By 3.3 h, Ͻ50% were positive after any dose (Fig. 2) . In this cohort of occasional to moderate smokers, 0%-5.9% completers had blood THC Ն5 g/L at baseline (all conditions), with Յ21.1% THC Ն5 g/L by 2.3 h. Thus, 78.9% of occasional to moderate cannabis smokers were negative after only 2.3 h with a THC Ն5 g/L cutoff.
Pharmacokinetic parameters for all participants are presented in online Supplemental Tables 5-11 . There were no significant differences [P Ͼ 0.44, MannWhitney U (exact) test] between completers and noncompleters in cannabis smoking history, age, weight, or body mass index. High interindividual variability was observed in THC, 11-OH-THC, THCCOOH, and THCCOOH-glucuronide concentrations. Observed THC, 11-OH-THC, CBD, and CBN t max occurred immediately postinhalation, whereas THCCOOH, THCglucuronide, and THCCOOH-glucuronide t max values reflected additional time needed for further metabolism. After active doses, full-study population median THC and 11-OH-THC observed t last occurred at 3.5-6.4 and 1.4 -3.3 h, respectively. Median THCCOOH and THCCOOH-glucuronide t last values extended Ն8.3 h. CBD and CBN t last occurred within 0.5 h.
On the basis of pharmacokinetic data, Participant 25 may have accessed active cannabis during his Pϩ session, despite being under observation throughout his stay (see online Supplemental Fig. 3 ). Blood and plasma THC C max were 18.5 and 25.6 g/L. This participant's oral fluid indicated he was negative on admission the night before dosing but positive just before dosing. It is possible these high concentrations resulted from dosing error; however, there was no indication from careful record review that an error occurred. These data were excluded from pharmacokinetic data analysis. 
THCCOOH-GLUCURONIDE/THCCOOH RATIOS
Blood and plasma THCCOOH-glucuronide/THC-COOH ratios decreased immediately (within the first half-hour postdose) after inhaling active cannabis and subsequently rose, with substantial interindividual variability (see online Supplemental Fig. 5 
Discussion
Here we obtained complete data for blood and plasma phase I and II cannabinoid concentrations following vaporized cannabis, with and without low-dose alcohol. Inhaling vaporized bulk cannabis produced blood and plasma cannabinoid concentrations and pharmacokinetic curves similar to those of smoking (11, (15) (16) Tables 3 and 4) . c Significant overall alcohol dose effect (P < 0.05) by factorial repeated-measures ANOVA (see Tables 3 and 4) . d Overall cannabis P <0.06 by factorial repeated-measures ANOVA. Post-hoc analysis revealed significant low and high vs placebo cannabis effect, but no significant low vs high cannabis effect (see Tables 3 and 4 ). e Significant overall alcohol-cannabis effect (P < 0.05) by factorial repeated-measures ANOVA (see Tables 3 and 4) . THCcontent:placebo0.008%(0.002%),low2.9%(0.14%),high6.7%(0.05%).Horizontaldottedlineindicatesanalytelimitofquantification.* Overall P < 0.006 (Friedman ANOVA),n=19. # Overall P < 0.05. a P < 0.006 (placebo vs high, no alcohol). b P < 0.006 (placebo vs high, with alcohol). c P < 0.006 (placebo vs low, no alcohol).
d P < 0.006 (placebo vs low, with alcohol). e P < 0.006 (low vs high, no alcohol). f P < 0.006 (low vs high, alcohol).
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Vaporized Blood and Plasma Cannabinoids with or without Alcohol individual plasma THC after 1.7%, 3.4%, and 6.8% THC (11 ) . Cigarettes were halved; half were smoked, the other half vaporized. The 2 routes produced similar plasma THC concentrations and 6-h AUCs. Pulmonary THC intake after vaporization is similar to smoking (22 ) , with approximately 54% of the THC dose delivered to the balloon for inhalation, and 30%-40% exhaled. Smoking cannabis also has factors that decrease THC delivery relative to dose. Approximately 23%-30% of THC is lost by pyrolysis and 40%-50% as sidestream smoke (23 ) . Our blood and plasma study corroborates evidence that vaporization is an effective alternative administration route (mitigating health concerns from combustion byproduct inhalation due to the lower vaporization temperature), delivering THC in a similar manner to smoking and producing similar cannabinoid concentration profiles. Participants inhaled ad libitum by controlling inhalation rate, depth, and hold time in the lungs (inhalation topography, allowing individual self-titration on the basis of pharmacological response) (24 ) , contributing to substantial interindividual variability in cannabinoid concentration profiles. Significantly higher C max and AUC 0 -8.3h were observed for THC, THC-glucuronide, 11-OH-THC, THCCOOH, THCCOOH-glucuronide (only when accounting for baseline), and CBD after H vs L cannabis. However, 52.6% of completers' withinindividual blood THC C max values indicated self-titration: 21.0% had L and H C max values within 20% of each other for Ն1 alcohol condition, and 31.6% had higher C max values after L than H doses. For most compounds, noticeable median/range differences for the same THC potency with (ϩ) and without (Ϫ) alcohol (Table 2 and   online Supplemental Table 2 ) generally occurred only after the H dose; L doses produced consistent C max and AUCs. This also supports self-titration: participants required less self-titration at the L dose to achieve intended results, likely consuming the full amount. More variability after the H dose suggests greater self-titration. Apart from inhalation topography, factors affecting vaporized THC delivery include heating temperature, number of balloon fillings, cannabis amount and blend, and length of time between volatilization and inhalation (owing to possible THC adherence to the balloon) (12, 22, 25 ) .
Most previous cannabis and alcohol concentrations were reported from roadside drugged driving prevalence studies, providing no information about possible cannabinoid pharmacokinetic differences with alcohol (8 ) . Some controlled-administration experiments provided limited cannabis and alcohol pharmacokinetic data in relation to performance impairment assessments (26 -27 ) . We showed significantly higher THC C max with alcohol in blood and plasma, and additionally for other cannabinoids. Alcohol-cannabis interactions were statistically significant in blood 11-OH-THC C max , but not plasma, limiting conclusions from this observation. One study (28 -29 ) directly examined combined alcohol and cannabis pharmacokinetics in chronic smokers; but with only 1 cannabis dose (400 g/kg THC) and 3 alcohol conditions (placebo, approximately 0.05%, and approximately 0.07% blood alcohol concentration). Alcohol before smoking did not significantly affect THC C max (28 -29 ) . Similar results were reported in another study, which also found no significant differences in plasma THC C max or AUC after ingesting 420 and 850 mg/kg alcohol vs placebo alcohol (cannabis smoked 0.25 h post- alcohol) (30 ) . Plasma THC increased nonsignificantly but dose-dependently with increasing alcohol. Plasma THC 0.3 h postsmoking was "generally higher" 0.8 h after alcohol than without alcohol (26 ) , but no statistics were provided. Moderate alcohol (0.35 g/kg) produced significantly higher plasma THC within 15 min after start of smoking, but significant differences were not observed over a full 90-min THC curve (31 ) . In contrast, 0.7 g/kg alcohol produced significantly lower serum THC 1 h postsmoking (28 ) . Generally, these results corroborate ours, as observed THC C max occurred immediately postinhalation (within 15 min).
Because alcohol increased THC and 11-OH-THC C max but not AUC 0 -8.3h (even accounting for baseline), it is possible that alcohol affected absorption (higher concentrations immediately postinhalation). Possible alcohol-induced perfusion and distribution changes affect other drugs (28, 32 ) . Acute alcohol increases cardiac output within 30 min (33 ), possibly leading to more rapid THC absorption during inhalation due to increased pulmonary capillary flow. In contrast to prior studies with a time delay (Ն0.3 h) between alcohol and cannabis to allow for alcohol absorption (26 -29, 31 ) , the present experiment administered cannabis and alcohol concurrently; the entire dosing process required Յ20 min. Our approach retains real-world validity for recreational intake. It is also possible that our higher blood cannabinoid C max reflects less careful cannabis selftitration after alcohol.
Overall, we observed minimal alcohol effects on THC metabolism. Higher blood and plasma 11-OH-THC C max values (Table 2) could be due to increased metabolism, but probably result from higher THC C max . Blood THCCOOH-glucuronide C max occurred earlier with alcohol (ϩ), but plasma THCCOOH-glucuronide C max did not. Nonglucuronidated THCCOOH t max was unaffected by alcohol or cannabis condition in either matrix. Although the alcohol-cannabis interaction on metabolite 11-OH-THC t last in blood was statistically significant, it was based only on L and H cannabis doses (too many negative samples after placebo) and no clear pattern emerged. Thus, it does not appear to be clinically significant. No alcohol differences emerged at specific collection times, and there were no alcohol effects on THCCOOH concentrations. Limited other data are available on alcohol effects on cannabinoid metabolites (28 -29 ) . Although lower THCCOOH was observed after alcohol than placebo alcohol over 4 h (28 ), the effect was not significant owing to interindividual variability from prior cannabis smoking history. Our observations were similar (see online Supplemental Figs. 1 and 2 ). Participants 7, 13, and 22 had Ն10 g/L blood THCCOOH and Ն40 g/L blood THCCOOHglucuronide at baseline in Ն4 sessions and Ն1 baseline blood THC Ն1.4 g/L. Participant 7 additionally had 1 session with baseline 11-OH-THC 1.0 g/L. In all 6 sessions, participants 9 and 31 had Ն72.4 g/L baseline THCCOOH-glucuronide, Ն17.9 g/L THCCOOH, and Ն1.4 g/L THC. These 5 participants were likely the most frequent smokers in our cohort. Fabritius et al. (34 ) recently proposed that free blood THCCOOH thresholds differentiated occasional (Յ3 g/L) from frequent (Ն40 g/L) cannabis smokers, although 38.7% of occasional smokers' samples had THCCOOH Ͼ3 g/L and 83.6% of frequent smokers' samples had THCCOOH Յ40 g/L. By these criteria, 52.6% of our completers would be considered occasional smokers; the others fell between categories. Other factors in THCCOOH and THCCOOH-glucuronide interpretation include metabolism time and residual cannabinoids (acute vs chronic exposure). Observed THCCOOHglucuronide t max occurred later (median Ն1.4 h) than THCCOOH t max (median Ͻ0.5 h) ( Table 2 ), owing to the additional phase II metabolic process. THC-COOH and THCCOOH-glucuronide median and range concentration values were considerably lower when accounting for baseline, highlighting the effect of residual cannabinoid presence. THCCOOHglucuronide/THCCOOH ratios and variability (see online Supplemental Fig. 5 ) were similar to after smoking in occasional smokers (16 ) .
This study has multiple strengths. With extensive vaporized cannabis pharmacokinetic data, we confirm the utility of vaporization as a viable and effective cannabis-smoking alternative. We also characterize cannabinoid blood and plasma pharmacokinetics with concurrent alcohol, by use of gray-top Vacutainers, the collection device most commonly used in forensic settings. Alcohol effects on cannabinoid pharmacokinetics are of interest due to the commonality of coingestion. Combining these drugs affects performance impairment (5 ), possibly in part owing to higher cannabinoid concentrations. Our data provide a valuable pharmacokinetic reference for clinicians regarding future therapeutic use of vaporized cannabis. We also explicitly illustrate individual variability in inhalation behavior, documenting evidence of self-titration in half of participants. Increasing THC potency affects people differently, depending on cannabis use history. An additional strength is inclusion of phase II THC-and THCCOOHglucuronides, as well as minor cannabinoids CBD and CBN. Limited blood and plasma controlledadministration data exist for these compounds (15) (16) (17) 35 ) . Metabolites provide valuable information on smoking history and time since last intake (34, 36 ) . No study to date examined phase II metabolites after vaporization and alcohol; these data improve blood and plasma interpretation by toxicologists as medical and recreational cannabis prevalence expands. THCglucuronide is detected at low concentrations, within 0.5 h postsmoking. CBD and CBN were not detected after 0.42 h in this study, so these compounds have utility as recent-use markers in blood. No known study to date detected CBD or CBN in blood or plasma after 2.1 h postinhalation (15) (16) , although controlled smoked administration studies usually contained low (Յ1 mg) CBD and CBN doses. Blood collection may be delayed after an accident or traffic stop (37 ) , making it unlikely that these compounds will be detected. Karschner et al. (35 ) reported CBD t max 1.0 -5.5 h after Sativex (1:1 CBD:THC oromucosal spray, 5 and 15 mg CBD). This result highlights CBD relevance in forensic cannabinoid testing, given increasing medical cannabis prevalence. We recommend controlled administration studies of smoked and vaporized high-CBD cannabis strains, used for antiepileptic, antiemetic, antiinflammatory, and antipsychotic effects (38 -39 ) .
Study limitations include blood and plasma collections for only 8.3 h. Additionally, we did not directly compare vaporized cannabis to smoking to fully evaluate relative bioavailability. This investigation focused on participants with self-reported occasional to moderate cannabis intake histories; additional research is needed to characterize vaporized cannabis and alcohol pharmacokinetics in chronic frequent smokers.
Different THC cutoffs yielded different positivity rates (Fig. 2) . At 1 g/L, THC was positive in Ն42.1% of participants 4.8 h after active (L and H) and Ն27.8% after placebo, owing to residual THC from previous self-administration. With THC Ն2 g/L, 10.5%-15.8% were positive 3.3 h after L and 36.8%-42.1% after H doses. THC Ն5 g/L cutoffs resulted in only 1 THC-positive participant at 3.3 h. We expect positivity rates to be higher and for longer postvaporization in frequent smokers (6 ), thus warranting investigation. These debated per se cutoffs yield different detection windows in these occasional to moderate smokers, with 2 g/L limiting the window to approximately 4.8 h postdose (Fig. 2) , similar to the window of acute intoxication (40 ) . A higher 5-g/L cutoff results in a short detection window for occasional to moderate smokers-shorter than impairment windows (5, 40 ) -emphasizing the challenge in establishing appropriate science-based per se cannabis drugged driving legislation. Role of Sponsor: NHTSA played a direct role in the design of the study and review and interpretation of data. The sponsors did not play a role in review and interpretation of data or final approval of manuscript.
